Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Miaoyan Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9576-6508; OpenAlex author ID A5110689328. Sources: OpenAlex.

Their work

Papers
29 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2019: 2 papers · 2020: 3 papers · 2021: 4 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 5 papers

Papers 29

  1. Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer. Co-author DOI 10.1002/advs.202521844↗
  2. Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. Co-author DOI 10.1002/cam4.72083↗
  3. A pilot study of nectin-4-targeted radioligand [68Ga]Ga-FZNR-1 in patients with pancreatic ductal adenocarcinoma: head-to-head comparison with [18F]-FDG. First author DOI 10.1007/s00259-025-07609-0↗
  4. Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. First author DOI 10.1016/j.ccell.2026.08.012↗
  5. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  6. The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway. Co-author DOI 10.1016/j.tranon.2025.102346↗
  7. A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2025.102364↗
  8. A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adeno… First author DOI 10.1038/s41392-025-02530-2↗
  9. Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarci… Co-author DOI 10.1186/s12916-025-04078-y↗
  10. Tumor Volume Evaluation is a Superior Predictor of Prognosis Compared to RECIST in Metastatic Pancreatic Ductal Adenocarcinoma Undergoing Immunochemotherapy Co-author DOI 10.21203/rs.3.rs-7634457/v1↗
  11. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  12. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12916-024-03581-y↗
  13. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.03.037↗
  14. Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101561↗
  15. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  16. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Co-author DOI 10.3390/ijms24043270↗
  17. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… Co-author DOI 10.1016/j.csbj.2022.07.029↗
  18. Pyroptosis-related lncRNA pairs to estimate the molecular features and prognostic outcomes of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101524↗
  19. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09863-z↗
  20. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12920-022-01371-0↗
  21. Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines". Co-author DOI 10.1097/sla.0000000000004291↗
  22. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  23. A Novel Validated Recurrence Stratification System Based on 18F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.650266↗
  24. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Co-author DOI 10.7150/ijbs.59117↗
  25. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. First author DOI 10.1186/s12943-020-01167-9↗
  26. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction. Co-author DOI 10.18632/aging.104134↗
  27. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Co-author DOI 10.7150/thno.40566↗
  28. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligome… Co-author DOI 10.1136/bmjopen-2019-033452↗
  29. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40425-019-0703-0↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 26 shared papers, 2019–2026 · strength 4.55
  2. Si Shi · 20 shared papers, 2019–2026 · strength 3.27
  3. Jie Hua · 17 shared papers, 2019–2026 · strength 2.63
  4. Qingcai Meng · 15 shared papers, 2019–2026 · strength 2.27
  5. Bo Zhang · 11 shared papers, 2020–2023 · strength 1.66
  6. Jin Xu · 10 shared papers, 2019–2026 · strength 1.49
  7. Wei Wang · 9 shared papers, 2021–2026 · strength 1.47
  8. Chen Liang · 8 shared papers, 2019–2026 · strength 1.17
  9. Jin Xu · 5 shared papers, 2022–2026 · strength 0.92
  10. Siyuan Lu · 5 shared papers, 2022–2023 · strength 0.77
  11. Jialin Li · 3 shared papers, 2023–2026 · strength 0.63
  12. Rong Tang · 2 shared papers, 2026 · strength 0.53
  13. Mingwei Dong · 2 shared papers, 2025–2026 · strength 0.49
  14. Shaoli Song · 2 shared papers, 2021–2026 · strength 0.43
  15. Jiang Liu · 4 shared papers, 2019–2021 · strength 0.43
  16. Yiyin Zhang · 4 shared papers, 2019–2020 · strength 0.41
  17. Xueli Bai · 2 shared papers, 2024–2025 · strength 0.38
  18. Zhen Tan · 2 shared papers, 2020–2026 · strength 0.37
  19. Jin Xu · 2 shared papers, 2022 · strength 0.30
  20. Chunjuan Jiang · 1 shared paper, 2026 · strength 0.29
  21. Ying Liu · 1 shared paper, 2026 · strength 0.27
  22. Jianhui Yang · 1 shared paper, 2026 · strength 0.27
  23. Qiong Du · 1 shared paper, 2026 · strength 0.27
  24. Zeyin Rong · 1 shared paper, 2026 · strength 0.27
  25. Xu Jk · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.